Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + dasatinib + vinorelbine
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination chemotherapy regimen consisting of capecitabine, dasatinib, and vinorelbine. Capecitabine is an oral prodrug that is converted to 5-fluorouracil in the body, interfering with DNA production to stop cancer cell growth. Vinorelbine is a vinca alkaloid that disrupts microtubule formation during cell division, preventing cancer cells from dividing. Dasatinib is a tyrosine kinase inhibitor that targets multiple oncogenic pathways including BCR-ABL, SRC, c-KIT, EPHA2, and PDGFR-beta. This combination has been used in the treatment of advanced breast cancer, particularly in patients who have been previously treated with anthracyclines and taxanes.
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)EPHA2 (Ephrin type-A receptor 2)SFK (SRC family kinases)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on capecitabine + dasatinib + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + dasatinib + vinorelbine.